Company intelligence / Profile preview

Genomind

King of Prussia, Pennsylvania, United Statesgenomind.com ↗

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

Genomind’s pharmacogenetic tests are commercially available. The company reports adoption by over 15,000 healthcare providers. Clinical results focus on improved medication selection for mental health patients through actionable genetic insights; no traditional drug clinical trial data as the products are diagnostics. The Mental Health Map provides consumers with genetic insights into mental wellness traits but does not guide medication.

Therapeutic areas: PsychiatryNeurology
Modalities: Diagnostic test (Pharmacogenetic testing)Digital health platform
Industry: Molecular Diagnostics

Partnerships

Evexia Diagnostics

Beyond the preview

Go deeper on Genomind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomind.

Explore the full profile